nodes	percent_of_prediction	percent_of_DWPC	metapath
Trametinib—MAP2K1—forebrain—attention deficit hyperactivity disorder	0.0683	0.123	CbGeAlD
Trametinib—MAP2K2—forebrain—attention deficit hyperactivity disorder	0.0602	0.108	CbGeAlD
Trametinib—MAP2K1—cardiovascular system—attention deficit hyperactivity disorder	0.0578	0.104	CbGeAlD
Trametinib—MAP2K2—cardiovascular system—attention deficit hyperactivity disorder	0.0509	0.0914	CbGeAlD
Trametinib—MAP2K2—midbrain—attention deficit hyperactivity disorder	0.0397	0.0714	CbGeAlD
Trametinib—MAP2K1—nervous system—attention deficit hyperactivity disorder	0.0371	0.0667	CbGeAlD
Trametinib—MAP2K1—central nervous system—attention deficit hyperactivity disorder	0.0357	0.0642	CbGeAlD
Trametinib—MAP2K1—cerebellum—attention deficit hyperactivity disorder	0.0349	0.0627	CbGeAlD
Trametinib—MAP2K2—nervous system—attention deficit hyperactivity disorder	0.0327	0.0587	CbGeAlD
Trametinib—MAP2K2—central nervous system—attention deficit hyperactivity disorder	0.0314	0.0565	CbGeAlD
Trametinib—MAP2K2—cerebellum—attention deficit hyperactivity disorder	0.0307	0.0552	CbGeAlD
Trametinib—MAP2K1—brain—attention deficit hyperactivity disorder	0.0284	0.051	CbGeAlD
Trametinib—MAP2K2—brain—attention deficit hyperactivity disorder	0.025	0.0449	CbGeAlD
Trametinib—MAP2K2—Uptake and actions of bacterial toxins—SNAP25—attention deficit hyperactivity disorder	0.0193	0.0436	CbGpPWpGaD
Trametinib—MAP2K1—Uptake and actions of bacterial toxins—SNAP25—attention deficit hyperactivity disorder	0.0181	0.0408	CbGpPWpGaD
Trametinib—MAP2K2—Hypothetical Network for Drug Addiction—DRD1—attention deficit hyperactivity disorder	0.0149	0.0335	CbGpPWpGaD
Trametinib—MAP2K2—Hypothetical Network for Drug Addiction—DRD4—attention deficit hyperactivity disorder	0.014	0.0315	CbGpPWpGaD
Trametinib—MAP2K1—Hypothetical Network for Drug Addiction—DRD1—attention deficit hyperactivity disorder	0.0139	0.0313	CbGpPWpGaD
Trametinib—MAP2K2—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—HTR2A—attention deficit hyperactivity disorder	0.0133	0.0299	CbGpPWpGaD
Trametinib—MAP2K1—Hypothetical Network for Drug Addiction—DRD4—attention deficit hyperactivity disorder	0.0131	0.0295	CbGpPWpGaD
Trametinib—MAP2K2—Hypothetical Network for Drug Addiction—DRD2—attention deficit hyperactivity disorder	0.013	0.0293	CbGpPWpGaD
Trametinib—MAP2K1—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—HTR2A—attention deficit hyperactivity disorder	0.0124	0.028	CbGpPWpGaD
Trametinib—MAP2K1—Hypothetical Network for Drug Addiction—DRD2—attention deficit hyperactivity disorder	0.0122	0.0274	CbGpPWpGaD
Trametinib—MAP2K2—L1CAM interactions—ANK3—attention deficit hyperactivity disorder	0.011	0.0247	CbGpPWpGaD
Trametinib—MAP2K2—Insulin Signaling—SNAP23—attention deficit hyperactivity disorder	0.0105	0.0237	CbGpPWpGaD
Trametinib—MAP2K1—L1CAM interactions—ANK3—attention deficit hyperactivity disorder	0.0102	0.0231	CbGpPWpGaD
Trametinib—MAP2K2—NCAM signaling for neurite out-growth—CACNB2—attention deficit hyperactivity disorder	0.0102	0.0229	CbGpPWpGaD
Trametinib—MAP2K1—Insulin Signaling—SNAP23—attention deficit hyperactivity disorder	0.00982	0.0222	CbGpPWpGaD
Trametinib—MAP2K1—NCAM signaling for neurite out-growth—CACNB2—attention deficit hyperactivity disorder	0.00951	0.0214	CbGpPWpGaD
Trametinib—MAP2K2—NCAM signaling for neurite out-growth—CACNA1C—attention deficit hyperactivity disorder	0.0093	0.021	CbGpPWpGaD
Trametinib—MAP2K1—NCAM signaling for neurite out-growth—CACNA1C—attention deficit hyperactivity disorder	0.0087	0.0196	CbGpPWpGaD
Trametinib—CYP2C8—brain—attention deficit hyperactivity disorder	0.00865	0.0155	CbGeAlD
Trametinib—MAP2K2—Signaling by ERBB2—STUB1—attention deficit hyperactivity disorder	0.00852	0.0192	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by ERBB2—STUB1—attention deficit hyperactivity disorder	0.00797	0.018	CbGpPWpGaD
Trametinib—CYP3A4—nervous system—attention deficit hyperactivity disorder	0.00766	0.0138	CbGeAlD
Trametinib—CYP3A4—central nervous system—attention deficit hyperactivity disorder	0.00738	0.0133	CbGeAlD
Trametinib—MAP2K2—SHP2 signaling—BDNF—attention deficit hyperactivity disorder	0.0067	0.0151	CbGpPWpGaD
Trametinib—MAP2K1—SHP2 signaling—BDNF—attention deficit hyperactivity disorder	0.00627	0.0141	CbGpPWpGaD
Trametinib—MAP2K1—Neurotrophic factor-mediated Trk receptor signaling—BDNF—attention deficit hyperactivity disorder	0.00602	0.0136	CbGpPWpGaD
Trametinib—CYP3A4—Estrogen metabolism—COMT—attention deficit hyperactivity disorder	0.00451	0.0102	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—RTN4—attention deficit hyperactivity disorder	0.00448	0.0101	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—RTN4—attention deficit hyperactivity disorder	0.0042	0.00946	CbGpPWpGaD
Trametinib—MAP2K2—Axon guidance—ANK3—attention deficit hyperactivity disorder	0.00414	0.00933	CbGpPWpGaD
Trametinib—MAP2K2—Insulin Signaling—SNAP25—attention deficit hyperactivity disorder	0.0041	0.00924	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—ANK3—attention deficit hyperactivity disorder	0.00387	0.00873	CbGpPWpGaD
Trametinib—MAP2K1—Insulin Signaling—SNAP25—attention deficit hyperactivity disorder	0.00383	0.00865	CbGpPWpGaD
Trametinib—MAP2K1—FOXM1 transcription factor network—EP300—attention deficit hyperactivity disorder	0.00363	0.00819	CbGpPWpGaD
Trametinib—MAP2K1—IFN-gamma pathway—EP300—attention deficit hyperactivity disorder	0.00357	0.00804	CbGpPWpGaD
Trametinib—MAP2K1—Aryl Hydrocarbon Receptor—EP300—attention deficit hyperactivity disorder	0.00338	0.00762	CbGpPWpGaD
Trametinib—MAP2K2—BDNF signaling pathway—BDNF—attention deficit hyperactivity disorder	0.00324	0.0073	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—MB21D1—attention deficit hyperactivity disorder	0.0032	0.00721	CbGpPWpGaD
Trametinib—MAP2K1—BDNF signaling pathway—BDNF—attention deficit hyperactivity disorder	0.00303	0.00683	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—MB21D1—attention deficit hyperactivity disorder	0.00299	0.00675	CbGpPWpGaD
Trametinib—MAP2K2—Kit receptor signaling pathway—EP300—attention deficit hyperactivity disorder	0.00296	0.00667	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—ANK3—attention deficit hyperactivity disorder	0.00295	0.00666	CbGpPWpGaD
Trametinib—MAP2K2—Axon guidance—CACNB2—attention deficit hyperactivity disorder	0.00292	0.00658	CbGpPWpGaD
Trametinib—MAP2K2—MAPK Signaling Pathway—BDNF—attention deficit hyperactivity disorder	0.00286	0.00645	CbGpPWpGaD
Trametinib—MAP2K1—Kit receptor signaling pathway—EP300—attention deficit hyperactivity disorder	0.00277	0.00624	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—ANK3—attention deficit hyperactivity disorder	0.00276	0.00623	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—CACNB2—attention deficit hyperactivity disorder	0.00273	0.00615	CbGpPWpGaD
Trametinib—MAP2K1—MAPK Signaling Pathway—BDNF—attention deficit hyperactivity disorder	0.00268	0.00604	CbGpPWpGaD
Trametinib—MAP2K2—Axon guidance—CACNA1C—attention deficit hyperactivity disorder	0.00267	0.00601	CbGpPWpGaD
Trametinib—CYP2C8—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00258	0.00582	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.00253	0.00571	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—CACNA1C—attention deficit hyperactivity disorder	0.0025	0.00563	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—BDNF—attention deficit hyperactivity disorder	0.00242	0.00545	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.00237	0.00534	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—POLR3A—attention deficit hyperactivity disorder	0.00235	0.0053	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways in Glioblastoma—EP300—attention deficit hyperactivity disorder	0.00227	0.00513	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—POLR3A—attention deficit hyperactivity disorder	0.0022	0.00495	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways in Glioblastoma—EP300—attention deficit hyperactivity disorder	0.00213	0.0048	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—CACNB2—attention deficit hyperactivity disorder	0.00208	0.00469	CbGpPWpGaD
Trametinib—MAP2K2—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	0.00199	0.00448	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—CACNB2—attention deficit hyperactivity disorder	0.00195	0.00439	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—CACNA1C—attention deficit hyperactivity disorder	0.0019	0.00429	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—MB21D1—attention deficit hyperactivity disorder	0.00186	0.0042	CbGpPWpGaD
Trametinib—MAP2K1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	0.00186	0.00419	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—STUB1—attention deficit hyperactivity disorder	0.0018	0.00407	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—CACNA1C—attention deficit hyperactivity disorder	0.00178	0.00401	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—MB21D1—attention deficit hyperactivity disorder	0.00174	0.00393	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.0017	0.00383	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—STUB1—attention deficit hyperactivity disorder	0.00169	0.00381	CbGpPWpGaD
Trametinib—MAP2K2—Disease—STUB1—attention deficit hyperactivity disorder	0.00167	0.00376	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.00166	0.00375	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.00159	0.00358	CbGpPWpGaD
Trametinib—MAP2K1—Disease—STUB1—attention deficit hyperactivity disorder	0.00156	0.00352	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.00156	0.00351	CbGpPWpGaD
Trametinib—MAP2K2—TGF-beta Signaling Pathway—EP300—attention deficit hyperactivity disorder	0.00155	0.0035	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.00149	0.00337	CbGpPWpGaD
Trametinib—MAP2K1—TGF-beta Signaling Pathway—EP300—attention deficit hyperactivity disorder	0.00145	0.00328	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.0014	0.00315	CbGpPWpGaD
Trametinib—CYP3A4—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00138	0.00312	CbGpPWpGaD
Trametinib—CYP2C8—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.00138	0.00311	CbGpPWpGaD
Trametinib—CYP2C8—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.00137	0.00309	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—POLR3A—attention deficit hyperactivity disorder	0.00137	0.00308	CbGpPWpGaD
Trametinib—CYP2C8—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.00136	0.00307	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—POLR3A—attention deficit hyperactivity disorder	0.00128	0.00289	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.00117	0.00263	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.00115	0.0026	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.00109	0.00246	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—EP300—attention deficit hyperactivity disorder	0.00108	0.00244	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.00108	0.00243	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.00101	0.00227	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.001	0.00226	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000982	0.00221	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000963	0.00217	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.000942	0.00213	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000938	0.00212	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.000936	0.00211	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000919	0.00207	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.000907	0.00205	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000901	0.00203	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000891	0.00201	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.00088	0.00199	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.000876	0.00198	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.000849	0.00191	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000834	0.00188	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.000824	0.00186	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.00082	0.00185	CbGpPWpGaD
Trametinib—MAP2K2—Disease—SNAP25—attention deficit hyperactivity disorder	0.00079	0.00178	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.000767	0.00173	CbGpPWpGaD
Trametinib—CYP3A4—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000741	0.00167	CbGpPWpGaD
Trametinib—MAP2K1—Disease—SNAP25—attention deficit hyperactivity disorder	0.000739	0.00167	CbGpPWpGaD
Trametinib—CYP3A4—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.000736	0.00166	CbGpPWpGaD
Trametinib—CYP3A4—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.000731	0.00165	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000681	0.00154	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000637	0.00144	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000595	0.00134	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000574	0.0013	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000564	0.00127	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000557	0.00126	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000553	0.00125	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—EP300—attention deficit hyperactivity disorder	0.000541	0.00122	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000537	0.00121	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000536	0.00121	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000527	0.00119	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.00052	0.00117	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000518	0.00117	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—EP300—attention deficit hyperactivity disorder	0.000506	0.00114	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000501	0.00113	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000493	0.00111	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000487	0.0011	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000485	0.00109	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—EP300—attention deficit hyperactivity disorder	0.000477	0.00108	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000453	0.00102	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—EP300—attention deficit hyperactivity disorder	0.000447	0.00101	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—TPH2—attention deficit hyperactivity disorder	0.00039	0.000879	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.00039	0.000879	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000383	0.000864	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000356	0.000804	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000339	0.000765	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000317	0.000716	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000311	0.000702	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000303	0.000683	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000297	0.000669	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—EP300—attention deficit hyperactivity disorder	0.000278	0.000627	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—EP300—attention deficit hyperactivity disorder	0.00026	0.000587	CbGpPWpGaD
Trametinib—MAP2K2—Disease—EP300—attention deficit hyperactivity disorder	0.000257	0.000579	CbGpPWpGaD
Trametinib—MAP2K1—Disease—EP300—attention deficit hyperactivity disorder	0.00024	0.000542	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—COMT—attention deficit hyperactivity disorder	0.000236	0.000532	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000234	0.000529	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	0.000227	0.000513	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000209	0.000472	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000209	0.000472	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000206	0.000464	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000191	0.000431	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.00018	0.000405	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000168	0.000379	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000167	0.000377	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000159	0.000359	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—COMT—attention deficit hyperactivity disorder	0.000127	0.000286	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000126	0.000284	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—EP300—attention deficit hyperactivity disorder	0.000101	0.000228	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—EP300—attention deficit hyperactivity disorder	5.43e-05	0.000123	CbGpPWpGaD
